Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment-Reference-Cited by-同舟云学术

Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment

Published:2015-04-28 Issue:4 Volume:61 Page:633-639
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:Clin Infect Dis.

Author:

Cressey Tim R.,Avihingsanon Anchalee,Halue Guttiga,Leenasirimakul Prattana,Sukrakanchana Pra-ornsuda,Tawon Yardpiroon,Jaisieng Nirattiya,Jourdain Gonzague,Podany Anthony T.,Fletcher Courtney V.,Klinbuayaem Virat,Bowonwatanuwong Chureeratana

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/61/4/633/942014/civ346.pdf

Reference19 articles.

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf . Accessed 22 August 2013.

2. Tenofovir Disoproxil Fumarate

3. Pharmacokinetics and Dosing Recommendations of Tenofovir Disoproxil Fumarate in Hepatic or Renal Impairment

4. The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-infected Patients

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records;Antimicrobial Agents and Chemotherapy;2023-05-17

2. Tenofovir antiviral drug solubility enhancement with β-cyclodextrin inclusion complex and in silico study of potential inhibitor against SARS-CoV-2 main protease (Mpro);Journal of Molecular Liquids;2023-05

3. Combination Antiretroviral Therapy and Immunophenotype of Feline Immunodeficiency Virus;Viruses;2023-03-24

4. Chronic Kidney Disease in a Large National Human Immunodeficiency Virus Treatment Program;Healthcare;2022-08-08

5. Prevention of mother-to-child transmission of hepatitis B virus: protocol for a one-arm, open-label intervention study to estimate the optimal timing of tenofovir in pregnancy;BMJ Open;2020-09